目次

Executive Summary
Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Drug class
Market segments
Comparison by Drug class
Antacid - Market size and forecast 2020-2025
PPI - Market size and forecast 2020-2025
H2 receptor antagonist drugs - Market size and forecast 2020-2025
Pro-kinetic drugs - Market size and forecast 2020-2025
Market opportunity by Drug class

Customer landscape
Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
Alkem Laboratories Ltd.
AstraZeneca Plc
Bayer AG
Eisai Co. Ltd.
GlaxoSmithKline Plc
Johnson and Johnson Inc.
Lupin Ltd.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
The Procter and Gamble Co.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Drug class - Market share 2020-2025 (%)
22: Comparison by Drug class
23: Antacid - Market size and forecast 2020-2025 ($ million)
24: Antacid - Year-over-year growth 2020-2025 (%)
25: PPI - Market size and forecast 2020-2025 ($ million)
26: PPI - Year-over-year growth 2020-2025 (%)
27: H2 receptor antagonist drugs - Market size and forecast 2020-2025 ($ million)
28: H2 receptor antagonist drugs - Year-over-year growth 2020-2025 (%)
29: Pro-kinetic drugs - Market size and forecast 2020-2025 ($ million)
30: Pro-kinetic drugs - Year-over-year growth 2020-2025 (%)
31: Market opportunity by Drug class
32: Customer landscape
33: Market share By Geographical Landscape 2020-2025 (%)
34: Geographic comparison
35: North America - Market size and forecast 2020-2025 ($ million)
36: North America - Year-over-year growth 2020-2025 (%)
37: Europe - Market size and forecast 2020-2025 ($ million)
38: Europe - Year-over-year growth 2020-2025 (%)
39: Asia - Market size and forecast 2020-2025 ($ million)
40: Asia - Year-over-year growth 2020-2025 (%)
41: ROW - Market size and forecast 2020-2025 ($ million)
42: ROW - Year-over-year growth 2020-2025 (%)
43: Key leading countries
44: Market opportunity By Geographical Landscape ($ million)
45: Impact of drivers and challenges
46: Vendor landscape
47: Landscape disruption
48: Industry risks
49: Vendors covered
50: Market positioning of vendors
51: Alkem Laboratories Ltd. - Overview
52: Alkem Laboratories Ltd. - Product and service
53: Alkem Laboratories Ltd. - Key offerings
54: Alkem Laboratories Ltd. - Key customers
55: Alkem Laboratories Ltd. - Segment focus
56: AstraZeneca Plc - Overview
57: AstraZeneca Plc - Product and service
58: AstraZeneca Plc - Key offerings
59: AstraZeneca Plc - Key customers
60: AstraZeneca Plc - Segment focus
61: Bayer AG - Overview
62: Bayer AG - Business segments
63: Bayer AG - Key offerings
64: Bayer AG - Key customers
65: Bayer AG - Segment focus
66: Eisai Co. Ltd. - Overview
67: Eisai Co. Ltd. - Business segments
68: Eisai Co. Ltd. - Key offerings
69: Eisai Co. Ltd. - Key customers
70: Eisai Co. Ltd. - Segment focus
71: GlaxoSmithKline Plc - Overview
72: GlaxoSmithKline Plc - Business segments
73: GlaxoSmithKline Plc - Key offerings
74: GlaxoSmithKline Plc - Key customers
75: GlaxoSmithKline Plc - Segment focus
76: Johnson and Johnson Inc. - Overview
77: Johnson and Johnson Inc. - Business segments
78: Johnson and Johnson Inc. - Key offerings
79: Johnson and Johnson Inc. - Key customers
80: Johnson and Johnson Inc. - Segment focus
81: Lupin Ltd. - Overview
82: Lupin Ltd. - Product and service
83: Lupin Ltd. - Key offerings
84: Lupin Ltd. - Key customers
85: Lupin Ltd. - Segment focus
86: Pfizer Inc. - Overview
87: Pfizer Inc. - Business segments
88: Pfizer Inc. - Key offerings
89: Pfizer Inc. - Key customers
90: Pfizer Inc. - Segment focus
91: Takeda Pharmaceutical Co. Ltd. - Overview
92: Takeda Pharmaceutical Co. Ltd. - Product and service
93: Takeda Pharmaceutical Co. Ltd. - Key offerings
94: Takeda Pharmaceutical Co. Ltd. - Key customers
95: Takeda Pharmaceutical Co. Ltd. - Segment focus
96: The Procter and Gamble Co. - Overview
97: The Procter and Gamble Co. - Business segments
98: The Procter and Gamble Co. - Key offerings
99: The Procter and Gamble Co. - Key customers
100: The Procter and Gamble Co. - Segment focus
101: Currency conversion rates for US$
102: Research Methodology
103: Validation techniques employed for market sizing
104: Information sources
105: List of abbreviations